Evidence map›Paper›PMID 29124082›Full record

ReviewBone reports2017

Is osteoporosis an autoimmune mediated disorder?

Rosebella A Iseme, Mark Mcevoy, Brian Kelly, Linda Agnew, Frederick R Walker, John Attia

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Role of OSCAR Signaling in Osteoclastogenesis and Bone Disease.Frontiers in cell and developmental biology · 2021
    Review
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Rosebella A IsemeDepartment of Population and Reproductive Health, School of Public Health, Kenyatta University, P.O. Box 43844 -, 00100, Nairobi, Kenya.
Mark McevoySchool of Medicine & Public Health, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Brian KellySchool of Medicine & Public Health, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Linda AgnewBrain Behaviour Research Group, School of Science and Technology, University of New England, Armidale, NSW 2351, Australia.
Frederick R WalkerSchool of Medicine & Public Health, The University of Newcastle, Callaghan, NSW, 2308, Australia.
John AttiaSchool of Medicine & Public Health, The University of Newcastle, Callaghan, NSW, 2308, Australia.
University of Newcastle Australia · AUHunter Medical Research Institute · AUUniversity of New England · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last two decades have marked a growing understanding of the interaction occurring between bone and immune cells. The chronic inflammation and immune system dysfunction commonly observed to occur during the ageing process and as part of a range of other pathological conditions, commonly associated with osteoporosis has led to the recognition of these processes as important determinants of bone disease. This is further supported by the recognition that the immune and bone systems in fact share regulatory mechanisms and progenitor molecules. Research into this complex synergy has provided a better understanding of the immunopathogenesis underlying bone diseases such as osteoporosis. However, existing research has largely focussed on delineating the role played by inflammation in pathogenic bone destruction, despite increasing evidence implicating autoantibodies as important drivers of osteoporosis. This review shall attempt to provide a comprehensive overview of existing research examining the role played by autoantibodies in osteoporosis in order to determine the potential for further research in this area. Autoantibodies represent promising targets for the improved treatment and diagnosis of inflammatory bone loss.

Indexed as

AutoantibodiesBone mineral densityBone remodellingFracturesOsteoporosis

Identifiers

PMID29124082
PMCPMC5671387
OpenAlexW2765382251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.